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Researches in recent years show that progressive 
deterioration of the renal function caused by kidney 
diseases mainly relies on the severity of renal 
tubulointerstitial lesions (RTIL). Therefore, imp- 
ortance should be attached to RTIL. With its very 
complicated pathogenesis, RTIL is manifested as the 
local inflammation in renal interstitium at early stage, 
followed by secretion of cellular factor and then 
phenotype variation, apoptosis and excessive pro- 
liferation of renal tubular epithelial cell (RTEC), as 
well as increase in synthesis and decrease in 
degradation of extracellular matrix (ECM), causing 
excessive deposition of ECM and eventually renal 
interstitial fibrosis (RIF). Progress made in TCM 
researches on RTIL is summarized as follows.   
Researches on TCM Syndrome Patterns
In their multi-centered and prospective researches on 
the law governing the distribution of TCM syndrome 
patterns and its relationship with nephropathy in 286 
cases of IgA nephrosis (IgAN), Chen Xiangmei and 
others1 discovered that the syndrome of qi deficiency 
in the lung and spleen and the syndrome of 
deficiency of both qi and yin have pathological 
change mainly at grade ǿ–  ċ of Lee classification, the 
syndrome of yin deficiency in the liver and kidney 
mainly at grade ċ–Č and the syndrome of yang
deficiency in the spleen and kidney mainly at grade 
Č–č. The total score of the syndrome of yang
deficiency in the spleen and kidney as well as the 
scores of renal glomerular and tubular interstitial 
lesion are much higher than those of other 3 
syndrome patterns. The total score of the syndrome 
of yin deficiency in the liver and kidney and the score 
of RTIL are much higher than those of other 2 
syndrome patterns. The analysis on pathological data 
of 94 IgAN cases of blood stasis syndrome showed 
that it is mainly seen at grade ċ–čof Lee 
classification with the total score of RTIL and scores 
of infiltration of interstitial inflammatory cells, 
interstitial fibrosis and renal tubular atrophy much 
higher than those of non-blood stasis syndrome. 2 The 
scores of TCM symptoms and renal biopsy of 409 
IgAN cases in another large sample research3 were 
divided into 3 kinds respectively. The results 
indicated: 1) External causes (wind-cold, wind-heat 
and damp-heat) and internal causes (blood-stasis, 
phlegm-damp and damp-heat) are obviously related 
to the infiltration of renal interstitial inflammatory 
cells and the deposition of tissue immune complex; 
2)Internal causes are closely related to cellular 
proliferation in tissues; and 3) Causes for deficiency 
of vital qi such as yin deficiency of the liver and 
kidney and yang deficiency of the spleen and kidney 
are closely related to RIF and glomerulosclerosis. 
The above-mentioned 3 researches indicated that 
IgAN cases of excess syndrome in TCM are mainly 
manifested as glomerular and tubular interstitial 
active pathological change while both active and 
chronic pathological change in blood stasis syndrome 
accounts for high percentage. The cases of deficiency 
syndrome in TCM, qi deficiency of the lung and 
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spleen and deficiency of qi and yin, are mainly 
manifested as active pathological change while 
chronic pathological change in yang deficiency of the 
spleen and kidney and yin deficiency of the liver and 
kidney accounts for high percentage and severe in 
degree, especially that of the former. Therefore, it is 
said that TCM differentiation of symptoms and signs 
for classification of syndromes is of valuable 
reference for inferring the pathological change in the 
kidney of IgAN patients. In their research on TCM 
syndrome manifestation of 44 patients with chronic 
aristolochic acid nephrosis (CAAN) mainly 
manifested as RTIL, Wang Yaoxian and others4
discovered that the syndrome of deficiency of both qi
and yin has the highest incidence of RTIL, and more 
than 50% of cases of the syndrome of yang
deficiency in the spleen and kidney has RTIL when 
renal function is not yet severely damaged in 
decompensatory stage, and that the incidence of RTIL 
in decompensatory stage of blood stasis syndrome is 
much higher than that of other excess syndromes and 
rising with the development of disease, indicating 
that CAAN is characterized by earlier and severe 
symptoms of yang deficiency and blood stasis on the 
basis of deficiency of both qi and yin.   
Researches on Chinese Drugs
1. Single Chinese drug 
Huang Qi (咘㡾 Radix Astragali Mongolici): On the 
basis of routine treatment with Western medicine, 
Chen Liping and others5 additionally used 
intravenous drip with 40 ml Huangqi injection to 
treat 60 cases of primary nephrosis syndrome. They 
discovered that it is obviously superior in decreasing 
urine N-acetyl-beta-D-glucosaminidase (NAG), 
ȕ2-microglobulin (ȕ2-MG), urinary retinol-binding 
protein (URBP), and 24-hour urine protein to 
Western medicine group. Its mechanism may be 1) 
reducing expression of monocyte chemoattractant 
protein-1 (MCP-1) to decrease aggregation and 
activation of inflammatory cells in renal tubules and 
interstitium to alleviate RIF,6 2) obviously reducing 
transforming growth factor-beta (TGF-ȕ1) and ȕig-h3
(ECM adhesive protein induced by TGF) and 
expression of mRNA, 7 and 3) increasing expression 
of C-met, the receptor of hepatocyte growth factor of 
renal interstitial mechanocyte, to play a role in 
protecting renal tubules and resisting RIF. 8    
Artificial Cordyceps: Wang Yongjun and others9 used 
artificial cordyceps to treat 210 RTIL patients with a 
much better effect than Baoshenkang group in 
improving creatinine-eliminating rate, urinary 
osmotic pressure, urine NAG, ȕ2-MG and Į1-MG. Its 
mechanism may be 1) promoting the proliferation of 
RTEC, reducing cellular lesion or promoting cellular 
repair and inhibiting the excessive expression of 
mRNA of RTEC,10 2) inhibiting apoptosis of RTEC,11 
and 3) inhibiting the expression of TGF-ȕ and 
Į-smooth muscle actin (Į-SMA) and decreasing the 
transformation of renal tubular epithelial inter- 
stitium.12
Matrine: It can obviously decrease the expression of 
connective tissue growth factor (CTGF) and Į-SMA 
of renal tubulointerstitium in unilateral ureteral 
obstruction (UUO) rat model,13 partly restore the 
expression of matrix metalloproteinase 3 (MMP-3), 
decrease the expression of tissue inhibitor of matrix 
metalloprotease-1 (TIMP-1), promote the degradation 
of ECM,14 and reduce the level of interleukin 6 (IL-6) 
and the expression of TGF-ȕ1 in adenine rat model,15 
thus play an obvious role in treating experimental 
RTIL. 
Da Huang (໻咘 Radix et Rhizoma Rhei Palmati): 
Researches in recent years confirmed that Da Huang 
( ໻ 咘  Radix et Rhizoma Rhei Palmati) can 
effectively prevent and treat chronic renal failure 
(CRF), attributing to rhein and emodin, its main 
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active ingredients. Emodin can inhibit the 
proliferation of renal interstitial fibroblasts (RIFS), 
induce their apoptosis and inhibit cellular growth 
factors and ECM. Rhein can reverse RTEC 
overgrowth induced by TGF-ȕ1, inhibit the synthesis 
of ECM, lower nuclear factor kB (NF-kB) and 
activity of Caspase-3, reduce apoptosis of RTEC,16 
obstruct multiplication of RIFS induced by TGF-ȕ1, 
inhibit RIFS activated by TGF-ȕ1 and antagonize 
expression and synthesis of fibronectin (FN).17 
According to the pharmacokinetic experiment on 
human body, Zhu Wei pointed out recently that rhein 
may be the sole active ingredient of Da Huang (໻咘
Radix et Rhizoma Rhei Palmati) to treat CRF.18  
Panax notoginseng saponins (PNS): PNS can inhibit 
excessive multiplication of RTEC induced by uremic 
serum and secretion of total collagen to raise 
MMP-1/TIMP-1 (ratio of genetic expression to 
protein secretion) which plays an important role in 
the occurrence of RIF, promote degradation of 
ECM,19 increase the expression of proliferating cell 
nuclear antigen (PCNA) in RTEC, decrease the 
expression of Į-SMA, reduce the expression of 
PCNA and Į-SMA in RIFS, inhibit trans- 
differentiation of RTEC induced by TGF-ȕ1 and 
IL-1Į, 20,21 thus giving play to the effect of preventing 
and treating RTIL. 
Glycyrrhizic acid (GA): Wang Huiling and others22
found that GA can remarkably improve the excretion 
of urine albumin and NAG and the level of blood 
creatinine in CAAN animal model group with an 
effect similar to that of prednisone. Its mechanism 
may be 1) improving the effect of aristolochic acid 
(AA) on inhibiting the multiplication of RTEC and 
improving cellular ultrastructure, 23 2) decreasing the 
expression of renal interstitial NF-kB, CTGF and 
TGF-ȕ1,24 and 3) inhibiting the release of 
endothelin-1 (ET-1) and angiotensin Ċ (Ang Ċ) by 
RTEC under the effect of AA. 
Hong Hua (㑶㢅 Flos Carthami): Ding Yueling and 
others found that Hong Hua can remarkably protect 
impaired RTEC to reduce RIF. Its mechanism is 
closely related to inhibiting TGF-ȕ1 and genetic 
expression of mRNA and c-fos. 25 
In addition, Dan Shen ( Ѝ খ Radix Salviae 
Miltiorrhizae), Ligustrazine, Hong Jing Tian (㑶᱃໽
Radix Rhodiolae), Triptolide, and Ginsenoside also 
have obvious effect of preventing and treating RTIL.      
2. Compound of Chinese drugs  
Formulation made from Huang Qi (咘㡾 Radix 
Astragali Mongolici) and Dang Gui (ᔧᔦ Radix 
Angelicae Sinensis). Scholars found in recent years 
that this recipe is good for preventing and treating 
RTIL with the effect similar to the angiotensin 
converting enzyme inhibitor (ACEI) and angiotensin 
receptor blocker (ARB). Its mechanism may be 1) 
inhibiting the generation and expression of Ang Ċ
and osteopontin in renal tissue and reducing the 
expression of TGF-ȕ1 and CTGF to decrease 
transdifferentiation of RTEC and synthesis of 
ECM,26,27 2) lowering the expression of tissue 
transglutaminase (tTG) which can make ECM protein 
chain form stable structure to resist the degradation 
of ECM,28 3) continuously strengthening the activity 
of endothelial nitric oxide synthase (ENOS) in renal 
tissue of UUO rat model to increase nitric oxide (NO) 
to reduce angiotasis and relieve ischemia and hypoxia 
in the kidney, 29 and 4) inhibiting the expression of 
bax, an antiapoptotic component in RTEC, and 
lowering the Bcl-2/bax to inhibit apoptosis of 
RTEC.30
Shenyan Fangshuai Ye ( 㚒 ♢ 䰆 㹄 ⎆ Renal 
failure-preventing liquid). It consists of Huang Qi (咘
㡾 Radix Astragali Mongolici), Dang Gui (ᔧᔦ
Radix Angelicae Sinensis), Hong Jing Tian (㑶᱃໽
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Radix Rhodiolae), Zhi Da Huang (ࠊ໻咘 Radix et 
Rhizoma Rhei Preparata), E Zhu (㥾ᴃ Rhizoma 
Curcumae) and Liu Yue Xue (᳜݁䲾 Herba Serissae). 
Its effect of reducing 24 h urine protein, NAG, serum 
creatinine (SCr) and blood urea nitrogen (BUN) in 
rats with obstructive renal failure is similar to that of 
Benazepril.31 Its mechanism may be lowering the 
expression of TGF-ȕ1 to decrease the level of Į-SMA, 
alleviate the excessive expression of collagen and 
delay the progress of RIF. 32
Yishen Ruanjian San (Ⲟ㚒䕃മᬷ Nourishing kidney 
and resolving mass powder). It consists of eight 
Chinese drugs including Huang Qi (咘㡾 Radix 
Astragali Mongolici), Dang Gui ( ᔧ ᔦ Radix 
Angelicae Sinensis), Dan Shen (Ѝখ Radix Salviae 
Miltiorrhizae), Zhi Bie Jia (♭努⬆Carapax Trionycis 
Preparata) and  Cordycepic mycelia. Chen Yipu and 
others33 confirmed in their research in vitro that this 
serum-containing recipe can reduce the expression of 
TGF-ȕ1, CTGF and TIMP-1 and mRNA of human 
RIFS and RTEC to antagonize AA-caused ECM 
accumulation but have no obvious influence on 
plasminogen activator inhibitor-1 (PAI-1). They also 
confirmed that this recipe can reduce the expression 
of the above-mentioned indexes including PAI-1 in 
renal tissues to relieve RIF of CAAN. 34
Shenluo Tong (㚒㒰䗮Clearing renal collaterals drug). 
It consists of Huang Qi (咘㡾 Radix Astragali 
Mongolici), Dang Gui (ᔧᔦ Radix Angelicae 
Sinensis), Dan Shen ( Ѝ খ Radix Salviae 
Miltiorrhizae), Chuan Xiong ( Ꮁ 㡢 Rhizoma  
Chuanxiong), Di Long (ഄ啭 Pheretima Aspergillum), 
Wu Shao She (РṶ㲛 Zaocys), Da Huang (໻咘
Radix et Rhizoma Rhei) and Jiang Can (ۉ㱩
Bombyx Batryticatus). Ding Yueling and others 
discovered that the recipe can alleviate pathological 
change in ultrastructure of renal tubules to protect 
RTEC. Its mechanism may be inhibiting the 
expression of renal tubular interstitial PCNA, and 
decreasing the expression of Į-SMA, fibronectin (FN) 
and laminin (LN) through reducing renin activity and 
Ang  levelĊ  and lowering the expression of TGF-ȕ1 
and mRNA to delay RIF. 35  
Fufang Biejia Ruangan Pian (໡ᮍ努⬆䕃㙱⠛
Compound tortoise shell tablet for softening liver). It 
consists of Huang Qi ( 咘 㡾 Radix Astragali 
Mongolici), Dang Gui (ᔧᔦ Radix Angelicae 
Sinensis), Bie Jia (努⬆ Carapax Trionycis), San Qi 
(ϝϗ Radix Notoginseng), Chi Shao (䌸㡡 Radix 
Paeoniae Rubra)ˈDong Chong Xia Cao (ހ㰿໣㤝
Cordyceps) and Lian Qiao (䖲㖬 Fructus Forsythiae). 
This is a new drug with definite effect of resisting 
hepatic fibrosis. Zhao Zongjiang and others proved in 
a series of researches that the recipe can obviously 
inhibit the expression of NF-kB and TGF-ȕ1 and 
mRNA in renal tissue of UUO rats with an effect 
similar to that of Benazepril.36,37 It can also 
remarkably increase the expression of MMP-9 in 
UUO rats, decrease the expression of TIMP-1 and 
promote the degradation of ECM38 to prevent and 
treat RIF effectively. 
Conclusion
The above-mentioned researches show that TCM 
syndrome patterns are instructive for inferring the 
pathological change in RTIL. The Chinese drugs 
mentioned above supplement qi, nourish the kidney, 
promote blood circulation, remove blood stasis, clear 
heat and eliminate toxin. From the response of the 
disease to the drugs applied, it can be suggested that 
deficiency of the spleen and kidney, blood stasis and 
toxic heat may be the main pathogenesis of RTIL. 
However, because of its complication and variation, 
there have been no enough systematic and profound 
researches on Chinese drugs for clinical treatment. As 
molecular biology is further adopted in TCM, the 
relationship between Chinese drugs and RTIL will be 
inevitably determined. Application of Chinese drugs 
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based on differentiation of syndromes guided by 
TCM theory will be prosperous in future.  
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